clinical trial · NCT04542499
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
AbbVie·phase3·completed·n = 507
Parkinson DiseaseTavapadonPlacebo
brief summary
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
started
Sep 23, 2020
primary completion
Jan 29, 2024
completion
Feb 15, 2024
last updated
Apr 4, 2025
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol